Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 14/20 | 0.58 |
| ▸ | F10 | P00742 | 12/20 | 0.58 |
| ▸ | PLG | P00747 | 12/20 | 0.58 |
| ▸ | PLAU | P00749 | 12/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.58 |
| ▸ | PLAT | P00750 | 9/20 | 0.58 |
| ▸ | HPN | P05981 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL688900 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL29614824 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL29692564 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL4259347 | 0.99 | F2 (0.56) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL419839 | 0.99 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29429330 | 0.99 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2874094 | 0.82 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29493199 | 0.78 | F2 (0.70) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2864097 | 0.76 | PLAU (0.52) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL6785673 | 0.75 | F2 (0.62) | F2F10PLGPLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208475-A1 | Process and apparatus comprising episcopic differential contrast (EDIC) microscopy plus epifluorescence microscopy (EF) for the detection or identification of biological materials on surfaces | UNIVERSITY OF SOUTHAMPTON (GB) | 2005-09-22 | — | — | US | claimed |
| US-20240148888-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4297783-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Children's Medical Center Corporation (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220280653-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220220436-A1 | ALGINATE DIALDEHYDE-COLLAGEN HYDROGELS AND THEIR USE IN 3D CELL CULTURE | KLOSTERMEIER, Stefanie (DE) | 2022-07-14 | — | — | US | disclosed |
| EP-4017532-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Children's Medical Center Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021041171-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10675244-B2 | Microvesicles derived from nucleated, mammalian cells and use thereof | MDIMUNE INC. (KR) | 2020-06-09 | — | — | US | disclosed |
| US-20180296483-A1 | MICROVESICLES DERIVED FROM NUCLEATED, MAMMALIAN CELLS AND USE THEREOF | MDIMUNE INC. (KR) | 2018-10-18 | — | — | US | disclosed |
| EP-2450032-B1 | MICROVESICLES DERIVED FROM NUCLEATED, MAMMALIAN CELLS AND USE THEREOF | MDIMUNE INC (KR) | 2018-09-05 | — | — | EP | disclosed |
| EP-1365643-A2 | MICROINJECTION ASSEMBLY AND METHODS FOR MICROINJECTING AND REIMPLANTING AVIAN EGGS | Avigenics, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1364205-A1 | PRODUCTION OF A MONOCLONAL ANTIBODY BY A TRANSGENIC AVIAN | Avigenics, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1313849-A2 | CLONED CELLS, EMBRYOS, AND AVIANS AND METHODS OF PRODUCING THEM | Avigenics, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003025146-A2 | PRODUCTION OF A TRANSGENIC AVIAN BY CYTOPLASMIC INJECTION | AVIGENICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002064727-A2 | MICROINJECTION ASSEMBLY AND METHODS FOR MICROINJECTING AND REIMPLANTING AVIAN EGGS | AVIGENICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002063293-A1 | PRODUCTION OF A MONOCLONAL ANTIBODY BY A TRANSGENIC AVIAN | AVIGENICS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020108132-A1 | Production of a monoclonal antibody by a transgenic chicken | AVIGENICS INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002020752-A2 | CLONED CELLS, EMBRYOS, AND AVIANS AND METHODS, OF PRODUCING THEM | AVIGENICS, INC. GEORGIA BIO-BUSINESS CENTER (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1137659-A1 | INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR WEIGHT KININOGEN AND PEPTIDE ANALOGS THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000027866-A1 | INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR WEIGHT KININOGEN AND PEPTIDE ANALOGS THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280653-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | ICAM1, VCAM1, EPCAM | KLKB1 616/4885F2 2056/4885F10 1440/4885 |
| US-20240148888-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | ICAM1, VCAM1, EPCAM | KLKB1 629/4885F2 3253/4885F10 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.